IL-2 R beta & IL-2 R alpha & IL-2 R gamma Overview
Molecule Name
Interleukin-2
Synonyms
IL-2 R beta & IL-2 R alpha & IL-2 R gamma
Drug Development Progress
Drugs in Clinical Trials43
Approved Drugs2
Highest Development StageApproved
Target Synonym
T-cell growth factor，IL2，Interleukin 2，T Cell Growth Factor，Aldesleukin，IL-2，TCGF，Involved In Regulation Of T-Cell Clonal Expansion，Interleukin-2，Lymphokine
Background
Both Interleukin-2 receptor subunit beta and Interleukin-2 receptor subunit gamma are receptor for interleukin-2. Common subunit for the receptors for a variety of interleukins. Interacts with SHB upon interleukin stimulation. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit.
IL-2 R beta & IL-2 R alpha & IL-2 R gamma Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Melanoma; Sarcoma, Kaposi | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Adenomatous Polyposis Coli; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Pancreatic Neoplasms; Solid tumours | Details |
| IBI-363 | IBI-363 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma; Melanoma; Mucosal Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| EQ-101 | EQ101; EQ-101; BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Leukemia, Large Granular Lymphocytic; Lymphoma, T-Cell, Cutaneous | Details |
| umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| SIM-0278 | ALM-223; SIM0278 | Phase 2 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Lupus Nephritis | Details |
| Imneskibart | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Carcinoma, Renal Cell; Melanoma; Solid tumours | Details |
| STK-012 | STK-012 | Phase 2 Clinical | Synthekine Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Neoplasms; Solid tumours | Details |
| STI-7349 | STI-7349; ILKN421H | Phase 2 Clinical | The Fourth Affiliated Hospital, Zhejiang University School Of Medcine | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| LAT-010 | LAT010; LAT-010 | Phase 2 Clinical | Latticon Antibody Therapeutics Inc | Neoplasm Metastasis; Solid tumours | Details |
| COYA-302 | COYA 302; COYA-302; COYA302 | Phase 2 Clinical | Coya Therapeutics Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease | Details |
| KB-707 | KB707; KB-707 | Phase 2 Clinical | Krystal Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours | Details |
| REGN-10597 | REGN-10597 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Melanoma; Neoplasms; Solid tumours | Details |
| SAR-444336 | SAR-444336; THOR-809 | Phase 2 Clinical | Sanofi | Colitis, Microscopic; Inflammation | Details |
| COYA-301 | COYA-301 | Phase 2 Clinical | Coya Therapeutics Inc | Alzheimer Disease | Details |
| Saltikva | MDB401B | Phase 2 Clinical | Salspera LLC, Sunshine Lake Pharma | Pancreatic Neoplasms | Details |
| Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 2 Clinical | Tilt Biotherapeutics Ltd | Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | National Cancer Institute, St. Jude Children'S Research Hospital | Neuroblastoma | Details | |
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| ODC-IL2 | ODC-IL-2; ODC-IL2; ODC-1L2 | Phase 1 Clinical | Trutino Biosciences Inc | Neoplasms; Solid tumours | Details |
| Etakafusp alfa | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | Solid tumours | Details |
| TEV-278 | TEV-278; TEV-‘278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Neoplasms | Details |
| HM-16390 | HM-16390; HM16390 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| EGL-003 | EGL-003 | Phase 1 Clinical | Egle Therapeutics | Autoimmune Diseases; Dermatitis, Atopic; Neoplasms | Details |
| KYS-202003-A | KYS-202003-A; KYS202003A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Solid tumours | Details |
| M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Breast Neoplasms; Colorectal Neoplasms | Details |
| DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| Dodekin | Phase 1 Clinical | Philogen Spa | Solid tumours | Details | |
| TEV-56278 | TEV-56278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Melanoma; Neoplasms; Solid tumours | Details |
| AttIL2-T cell therapy | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Osteosarcoma; Sarcoma; Soft Tissue Neoplasms | Details | |
| Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) | HV-101; HV101 | Phase 1 Clinical | Hangzhou Houwu Biomedical Technology Co Ltd, Hervor Therapeutics, Tcrcure Biopharma Ltd | Solid tumours | Details |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Alopecia Areata; Autoimmune Diseases; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic | Details |
| MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | Solid tumours | Details |
| CUG-252 | CUG-252 | Phase 1 Clinical | Cugene Inc | Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | Dermatitis, Atopic | Details |
| BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Propagermanium | SK-818; SK-818C | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Serocion | Japan | Hepatitis B | Sanwa Kagaku Kenkyusho Co Ltd | 1994-01-01 | Hepatitis B | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms | Details |